Presbyopia Drug Launch And Consumer Campaign Will Create Long-Term Opportunity

Catalysts

About LENZ Therapeutics

LENZ Therapeutics is a commercial-stage biopharma company focused on VIZZ, an aceclidine-based eye drop for presbyopia in adults.

What are the underlying business or industry changes driving this perspective?

• The approval and early U.S. launch of VIZZ as the first and only aceclidine based presbyopia drop positions LENZ in a large vision care category that affects roughly 128 million Americans. This can support prescription volume and revenue as awareness converts into ongoing use.
• Eye care professional adoption is already underway, with around 2,500 doctors prescribing VIZZ and 40% writing multiple prescriptions after only a few weeks. This can help build a recurring prescriber base that supports revenue visibility.
• LENZ has built broad professional reach with roughly 70,000 samples distributed to about 7,000 offices and reported 90% awareness among eye care professionals. This can shorten the time from launch to meaningful prescription volume and help operating leverage over fixed commercial costs.
• The planned shift to a consumer focused phase in early 2026, including a direct to consumer campaign fronted by Sarah Jessica Parker and pricing options such as a discounted three pack through e pharmacy, is aimed at driving patient pull through. This can influence top line growth and eventually contribute to earnings scale.
• Ex U.S. licensing, including agreements in China and Canada with upfront and potential milestone payments plus tiered double digit royalties, gives LENZ non U.S. exposure without building its own global sales infrastructure. This can add high margin revenue streams over time.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming LENZ Therapeutics's revenue will grow by 77.4% annually over the next 3 years.
• Analysts are not forecasting that LENZ Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate LENZ Therapeutics's profit margin will increase from -586.7% to the average US Pharmaceuticals industry of 19.7% in 3 years.
• If LENZ Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $23.6 million (and earnings per share of $0.61) by about August 2029, up from -$126.0 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 54.0x on those 2029 earnings, up from -1.1x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 17.2x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.24%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• VIZZ is launching a new drug category in presbyopia, and over the long term it is unclear how many of the roughly 128 million affected adults will consistently pay out of pocket for a daily eye drop. This could limit sustained prescription volumes and cap revenue and earnings growth.
• The company is investing heavily ahead of consumer demand, with Q3 2025 SG&A of US$27.6 million against no product revenue in the quarter and a net loss of US$16.7 million. If prescription growth does not scale as management expects, net margins and operating cash flow could remain under pressure for longer than planned.
• Early feedback points to transient stinging and redness and a need for doctors to manage expectations. If real world tolerability or patient satisfaction falls short of current anecdotal reports over a longer period, repeat use and refill rates could weaken, affecting revenue and earnings.
• The DTC push planned for Q1 2026, with a high profile spokesperson and a largely digital media plan, requires substantial marketing spend. If consumer response is weaker than anticipated, the step up in promotional costs could weigh on profitability and delay the move to positive operating cash flow.
• LENZ is relying on ex U.S. partners in China and Canada for milestones and tiered double digit royalties over time. Regulatory or commercial setbacks in those markets could reduce expected high margin income streams and limit the contribution to overall margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $26.83 for LENZ Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $60.0, and the most bearish reporting a price target of just $7.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $119.8 million, earnings will come to $23.6 million, and it would be trading on a PE ratio of 54.0x, assuming you use a discount rate of 7.2%.
• Given the current share price of $4.6, the analyst price target of $26.83 is 82.9% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.